CG OncologyCGON
CGON
About: CG Oncology Inc is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. The company's lead candidate, cretostimogene grenadenorepvec, is a targeted oncolytic intravesically delivered immunotherapy agent that is in two phase three trials (one high-risk BCG unresponsive NMIBC trial and one intermediate-risk NMIBC trial) and a phase two clinical study with a checkpoint inhibitor for high-risk BCG unresponsive NMIBC disease.
Employees: 113
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
79% more repeat investments, than reductions
Existing positions increased: 61 | Existing positions reduced: 34
34% more call options, than puts
Call options by funds: $1.15M | Put options by funds: $859K
13% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 24
4.46% more ownership
Funds ownership: 88.38% [Q4 2024] → 92.84% (+4.46%) [Q1 2025]
1% more funds holding
Funds holding: 140 [Q4 2024] → 142 (+2) [Q1 2025]
8% less capital invested
Capital invested by funds: $1.9B [Q4 2024] → $1.74B (-$160M) [Q1 2025]
17% less funds holding in top 10
Funds holding in top 10: 12 [Q4 2024] → 10 (-2) [Q1 2025]
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$23
11%
downside
Avg. target
$56
115%
upside
High target
$75
190%
upside
6 analyst ratings
5 positive
83%
1 neutral
17%
0 negative
0%
Morgan Stanley Jeffrey Hung | 101%upside $52 | Overweight Maintained | 19 May 2025 |
JP Morgan Brian Cheng | 59%upside $41 | Overweight Initiated | 2 May 2025 |
RBC Capital Gregory Renza | 163%upside $68 | Outperform Maintained | 29 Apr 2025 |
Cantor Fitzgerald Josh Schimmer | 190%upside $75 | Overweight Reiterated | 28 Apr 2025 |
HC Wainwright & Co. Andres Maldonado | 190%upside $75 | Buy Reiterated | 28 Apr 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 week ago
CG Oncology to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference
IRVINE, Calif., June 05, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare Conference in Miami Beach, FL on Tuesday, June 10, 2025, at 11:20 am ET.
Positive
Zacks Investment Research
3 weeks ago
CGON Stock Rallies 27% in a Month on Bladder Cancer Study Success
CG Oncology stock surges 27% in a month following superior efficacy data from its phase III study of cretostimogene for a bladder cancer indication.
Negative
Zacks Investment Research
1 month ago
CG Oncology, Inc. (CGON) Reports Q1 Loss, Lags Revenue Estimates
CG Oncology, Inc. (CGON) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.39. This compares to loss of $0.36 per share a year ago.
Neutral
GlobeNewsWire
1 month ago
CG Oncology Reports First Quarter 2025 Financial Results and Provides Business Updates
- Updated BOND-003 clinical results presented at AUA showing best-in-disease durability and tolerability data for Cohort C with 24-month complete response rate of 42.3% by K-M -- Promising early signal in Cohort P with 90.5% high-grade recurrence free survival at 3 and 9 months by K-M -- New enrollment completion date for Phase 3 PIVOT-006 in intermediate-risk non-muscle invasive bladder cancer (NMIBC) expected in the second half of 2025 -- Initiated CORE-008 Cohort CX evaluating the combination of cretostimogene and gemcitabine in patients with high-risk (HR) BCG-exposed NMIBC - IRVINE, Calif., May 13, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today reported financial results for the first quarter ended March 31, 2025, and provided business updates.
Negative
Zacks Investment Research
1 month ago
CG Oncology, Inc. (CGON) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
CG Oncology, Inc. (CGON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Positive
Zacks Investment Research
1 month ago
CG Oncology, Inc. (CGON) Surges 25.0%: Is This an Indication of Further Gains?
CG Oncology, Inc. (CGON) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Positive
Benzinga
1 month ago
CG Oncology's Bladder Cancer Drug Impresses Investors - Here's Why
75.5% complete response rate reported in BOND-003 Cohort C study for high-risk NMIBC patients unresponsive to BCG.
Positive
Investors Business Daily
1 month ago
CG Oncology Rockets On Its Johnson & Johnson-Rivaling Cancer Drug
Shares of CG Oncology catapulted Monday after the biotech unveiled promising results for a J&J-rivaling bladder cancer treatment.
Neutral
GlobeNewsWire
1 month ago
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeting
CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at AUA
Positive
Seeking Alpha
2 months ago
CG Oncology Looks Attractive At Current Prices (Rating Upgrade)
CG Oncology, Inc.'s lead asset, cretostimogene grenadenorepvec, shows promising efficacy in bladder cancer with competitive complete response rates in clinical trials. Recent data updates reveal a 74.5% CR rate in the BOND-003 trial and a 41.2% CR rate in a phase 1 trial for MIBC. A basic DCF valuation estimates CGON's enterprise value at $5.3bn, suggesting a price target of $69, about 3x the current price.
Charts implemented using Lightweight Charts™